Recursion Pharmaceuticals (RXRX) Goodwill (2020 - 2026)

Recursion Pharmaceuticals has reported Goodwill for 7 years, with the latest figure at $160.2 million in Q1 2026.

• For the quarter ending Q1 2026, Goodwill rose 1.3% year-over-year to $160.2 million; the trailing twelve-month figure through Mar 2026 stood at $160.2 million (up 1.3% YoY), and the FY2025 full-year result was $162.2 million, up 8.92% from the prior year.
• Goodwill for Q1 2026 stood at $160.2 million, down from $162.2 million in the prior quarter.
• The five-year high for Goodwill was $164.3 million in Q2 2025, with the low at $801000.0 in Q1 2022.
• Historically, Goodwill has averaged $75.4 million across 5 years, with a median of $52.1 million in 2023.
• Annual changes were most pronounced in 2023 — Goodwill surged 7455.06% — and 2024, when it slipped 13.98%.
• Recursion Pharmaceuticals' Goodwill stood at $801000.0 in 2022, then surged by 6398.88% to $52.1 million in 2023, then soared by 185.99% to $148.9 million in 2024, then climbed by 8.92% to $162.2 million in 2025, then declined by 1.23% to $160.2 million in 2026.
• The last three Goodwill figures came in at $160.2 million (Q1 2026), $162.2 million (Q4 2025), and $162.0 million (Q3 2025), per Business Quant data.